在系统性自身免疫性疾病中通过循环免疫复合体激活Fcγ受体,并通过CD19-CAR T细胞疗法降低其活性
Merle Freitag1, Philipp Kolb2,3, Valeria Falcone2,3
1Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Rheumatology (Oxford, England)
|December 3, 2025
概括
循环免疫复合体 (cIC) 在结合组织疾病 (CTD) 中具有生物活性,激活Fcγ受体. 它们的生物活性与疾病呈现相关,并在CTD患者的CD19-CAR T细胞治疗后得到改善.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 这是一种自身免疫力.
背景情况:
- 结合性组织疾病 (CTD) 中的自身抗体通过IgG复合体和Fcγ受体 (FcγR) 激活促进病理.
- 循环免疫复合体 (cICs) 连接了适应性和先天性免疫,但它们在CTD中的作用和检测尚未得到充分研究.
- 向CD19的CAR T细胞疗法对CTD有前途,突出显示了B细胞向治疗的重要性.
研究的目的:
- 开发和使用一种新的检测方法来评估含有IgG的cICs的生物活性.
- 调查CTD患者中cICs的存在和FcγR激活潜力 (生物活性).
- 在CTD中将cIC生物活性与临床表型和治疗反应相关联.
主要方法:
- 一个记者细胞平台被用来测量cIC的存在和生物活性.
- 对IgG自身抗体阳性CTD患者和对照进行了截面分析.
- 纵向分析追踪了接受CD19.CAR T细胞治疗的患者的cIC生物活性.
主要成果:
- 与健康对照组和患有牛皮关节炎的患者相比,CTD患者的cIC生物活性显著提高.
- 在所有研究的CTD中检测到cICs,包括全身性硬化症 (SSc) 和原发性Sjögren综合征 (SjS),具有个体变异性.
- 在SSc中,抗毒素酶I (Scl70) 阳性,扩散皮肤和肺部参与与增强的cIC生物活性相关.
- CD19.CAR T细胞治疗导致CTD患者cIC生物活性显著降低.
结论:
- 该研究证实CTD中存在FcγR引入的cIC.
- cIC生物活性与CTD的临床表现和治疗结果有关.
- 这些发现支持cIC作为CTD中的潜在生物标志物和治疗点.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
T Cell Activation and Clonal Selection
14.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.6K
Cell-mediated Immune Responses
83.3K
Overview
83.3K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

